Mirum Pharmaceuticals, Inc. (MIRM) Misses Q4 EPS by 155c

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q4 EPS of ($1.85), $1.55 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $99.41 million versus the consensus estimate of $95.4 million.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• AIG (AIG) call put ratio 4 calls to 1 put with a focus on June 26 weekly calls as share price up 3.9%
• AIG (AIG) on Watch Following Unconfirmed M&A Chatter